10 集

Interview and discussion from the 14th IGCS meeting in Vancouver, BC on various topics including screening, prevention, PARP inhibitors and latest drug development.

14th International Gynecologic Cancer Society (IGCS) Meeting ecancer

    • 醫學

Interview and discussion from the 14th IGCS meeting in Vancouver, BC on various topics including screening, prevention, PARP inhibitors and latest drug development.

    • video
    The Cancer Genome Atlas and high grade serous ovarian cancer: Dr Andrew Berchuck – Duke University Medical Center, Durham, US

    The Cancer Genome Atlas and high grade serous ovarian cancer: Dr Andrew Berchuck – Duke University Medical Center, Durham, US

    Dr Andrew Berchuck talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the Cancer Genome Atlas project, which aims to provide a comprehensive, genomic analysis of all of the most common cancer types.

    In addition, Dr Berchuck discusses how this atlas will aid in the treatment of high-grade serous ovarian cancer, which causes the most deaths from this disease. This research is done by looking at mutations and amplifications in the genome rather than a gene by gene analyses.

    For this type of cancer there are a large number of genomic mutations and this project provides a new way of looking at potential targets and causes of the different disease types. Other important points taken from genomic analysis are the negative effects of cytotoxics and detection of problems like Lynch syndrome.

    • 13 分鐘
    • video
    OCTAVIA trial: bevacizumab and paclitaxel treatment for ovarian cancer: Dr Antonio Gonzalez-Martin – MD Anderson Cancer Cente

    OCTAVIA trial: bevacizumab and paclitaxel treatment for ovarian cancer: Dr Antonio Gonzalez-Martin – MD Anderson Cancer Cente

    Dr Antonio Gonzalez-Martin talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the phase II OCTAVIA trial and the effects of combination therapy of bevacizumab and paclitaxel in ovarian cancer.

    The OCTAVIA trial combined the two strategies of adding bevacizumab to standard chemotherapy and changing the administration of paclitaxel to increase progression free survival.

    In addition to overall survival, there was also a hypothesis that paclitaxel had anti-angiogenic effects. The study used the same criteria as the ICON 7 trial except that this was a single arm study, so to provide information on efficacy.

    The results of the study were that 90% of patients could complete 6 cycles of chemotherapy with toxicity levels consistent with many phase III trials. The medium progression free survival was 23.7 months with a lower limit higher than 18 months.

    From this data, future studies hope to further investigate administering paclitaxel and bevacizumab to increase survival.

    • 8 分鐘
    • video
    Staging in endometrial cancer and sentinel node mapping: Dr Charles Levenback – MD Anderson Cancer Center, Houston, TX, USA

    Staging in endometrial cancer and sentinel node mapping: Dr Charles Levenback – MD Anderson Cancer Center, Houston, TX, USA

    Dr Charles Levenback talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about aggressively staging patients based on risk, condition and co-morbidity.

    As endometrial cancer occurs more frequently in elderly patients, with obesity, high blood pressure and diabetes also factors, the general approach is pre-operative biopsy, hysterectomy and analysis of the samples.

    The next staging depends upon the condition and invasion of the tumour. The problem with treatment and staging here is the lack of consensuses on the broad range of possible approaches.

    Dr Levenback explains sentinel node mapping and how he feels it could potentially replace the traditional staging methods as it would lead to better treatment and lower morbidity.

    • 7 分鐘
    • video
    GOG 209 study: optimal management of advanced endometrial cancer: Prof David Miller – University of Texas, Dallas, USA

    GOG 209 study: optimal management of advanced endometrial cancer: Prof David Miller – University of Texas, Dallas, USA

    Dr David Miller talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the GOG 209 study and drug regimens for endometrial cancer.

    Standard treatment of endometrial cancer usually involves a surgical treatment, as well as chemotherapy. However, in 20-30 percent of patients, where surgery is not possible, advanced endometrial cancer treatment focuses more on chemotherapy and biological therapies.

    The GOG 209 study looked to simplify treatment of advanced endometrial cancer, which consists of the three drug regimen of paclitaxel, doxorubicin and cisplatin. This course offered a clear survival advantage but has high toxicity and does not allow for use with targeted therapies.

    In a trial testing carboplatin and paclitaxel, normally used in ovarian cancer, it was discovered that this treatment was as useful as the three drug course, but less toxic. This result now opens the possibility for inclusion of targeted therapy as well.

    • 8 分鐘
    • video
    Effects of early ovarian cancer screening: Dr Ed Pavlik – University of Kentucky, Lexington, USA

    Effects of early ovarian cancer screening: Dr Ed Pavlik – University of Kentucky, Lexington, USA

    Dr Ed Pavlik talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the importance and methods for ovarian cancer screening.

    The early detection method, transvaginal ultrasound, allows for a diagnosis of 70 percent of stage one and two cases. Ovarian cancer has seven times less prevalence than breast cancer, but a 60 percent mortality rate if not detected in these early stages

    The method of transvaginal ultrasound uses serial screenings to compare structures to a number index and morphology index that detects abnormalities and monitors them over time.

    Dr Pavlik notes that most abnormalities resolve themselves, but this monitoring initiates immediate actions when required and prevents false positives.

    • 10 分鐘
    • video
    Sexual health during and after ovarian cancer treatment: Dr Susan Carr – Royal Women’s Hospital, Parkville, Australia

    Sexual health during and after ovarian cancer treatment: Dr Susan Carr – Royal Women’s Hospital, Parkville, Australia

    Dr Susan Carr talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the importance of patient sexual health during, and post, ovarian cancer treatment.

    Research shows that 50 percent of women will have a potentially long lasting sexual issue after diagnosis. These issues can stem directly and indirectly from the disease; however, patients feel unable to discuss them within the clinic.

    Many clinicians see the topic as taboo and many patients find no opportunity to express their concerns. Dr Carr notes that the topics covered are not just sex in a physical sense, but in a broader, emotional spectrum as well.

    The improvement needed in the clinic is the areas of awareness and an ability to communicate with the patient.

    • 6 分鐘

關於醫學的熱門 Podcast

ecancer的更多節目